Shalby Ltd Q1 FY27 Results

Shalby's consolidated revenue rose 11.7% YoY to ₹331.22 Cr (+15.2% QoQ) for Q1 FY27, but consolidated profit before tax fell 13.1% YoY to ₹19.70 Cr as core margins compressed — operating margin (OPM) slipped to 12.56% from 14.01% a year ago. Reported PAT (period total, before non-controlling interest) grew 36.7% YoY to ₹10.50 Cr, but this is almost entirely a function of a lower effective tax rate this quarter (46.7% vs 66.1% in Q1 FY26) rather than operating improvement — PBT itself declined. No street/consensus estimates for this quarter turned up in available coverage, so vsStreet is unknown. On a QoQ basis PAT fell 43.1% from ₹18.45 Cr in Q4 FY26, though that base included unusually large tax credits specific to the year-end quarter, making the sequential comparison less meaningful than the YoY read.

The margin compression traces to the Manufacturing & Trading of Implants (MedTech) segment: its revenue jumped 51.1% YoY to ₹42.41 Cr but its segment loss widened 15.8% YoY to ₹11.48 Cr, eating into the ₹31.18 Cr PBT the Healthcare Services segment generated (down 4.3% YoY from ₹32.57 Cr). Healthcare Services segment revenue grew just 7.6% YoY to ₹288.81 Cr, tracking below management's guided minimum 15% CAGR floor for the hospital and pharma business laid out on the Q4 FY26 call, and margins have not shown the 'continued improvement' management said it expected for FY27 — on both counts this quarter runs behind prior guidance, so vsGuidance is 'missed'. Standalone tells a similar but sharper story: standalone PBT fell 15.5% YoY and standalone PAT fell 2.5% YoY to ₹25.07 Cr even as standalone revenue grew 7.3% YoY — the wide gap between standalone (-2.5%) and consolidated (+36.7%) PAT growth is a basis divergence worth flagging, since the consolidated figure benefits far more from the lower tax rate.

The stock went into the print at ₹157.28, down 5.1% over the past month of trading.

For context: revenue is at a 6-quarter high.

The Board, at the same meeting, appointed Shanay Vikram Shah as Whole-Time Director for five years; no separate management press release accompanied this filing. The quarter's other developments include a ₹129.70 Cr working capital facility secured from Kotak Mahindra Bank (Jul 30) and disposal of a pending arbitration matter (Jun 27) — neither materially explains the P&L movement. Going into Q2 FY27, the print sets up two open questions: whether MedTech segment losses (₹11.48 Cr this quarter) narrow as it scales toward management's INR600-650 Cr by 2030 revenue target, and whether Healthcare Services growth re-accelerates toward the guided 15% floor, since the current 7.6% YoY pace and 12.56% OPM would need to improve materially to match the confident tone management struck on the Q4 FY26 call.